Cratal tablets 20 pcs.

• active ingredients: 1 tablet contains hawthorn fruit extract thick (Crataegiae fructus extractum spissum) (3.0-3.3:1), (extractant: ethanol 70% v/v), calculated on dry matter – 43 mg, stinging nettle extract thick (Leonuriae herba extractum spissum) (4.5-5.6:1), (extractant: ethanol 70% v/v), calculated on dry matter – 87 mg, taurine, calculated on 100% dry matter – 867 mg;
• excipients: microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal anhydrous silicon dioxide.

• hypersensitivity to the components of the drug;
• pronounced bradycardia and arterial hypotension.

The duration of treatment and dose are determined by the doctor individually. The drug is administered orally, 1-2 tablets 3 times a day before meals. The course of treatment is 3-4 weeks.

Do not exceed the recommended doses of the drug.

If symptoms persist or worsen during treatment with the drug, you should consult a doctor.

If you experience swelling of your ankles or feet, pain in the heart area that may spread to the left arm, upper abdomen, or neck, or shortness of breath, seek IMMEDIATE medical attention.

Use during pregnancy or breastfeeding

There is currently no data on the use of the drug during pregnancy or breastfeeding.

The drug is contraindicated for use during pregnancy.

If it is necessary to use the drug in breastfeeding women, breastfeeding should be discontinued for the period of treatment.

Children

There is no experience in using the drug to treat children.

Ability to influence reaction speed when driving vehicles or other mechanisms

During the period of treatment, patients taking Cratal should refrain from driving vehicles and potentially dangerous mechanisms.

Symptoms: hypersensitivity reactions, allergic reactions, dyspeptic reactions, general weakness, feeling of fatigue, dizziness, drowsiness, arterial hypotension, bradycardia.

Treatment: discontinuation of the drug and symptomatic therapy.

Possible manifestations of hypersensitivity, allergic reactions (including hyperemia, rashes, itching, swelling of the skin, urticaria), dyspeptic phenomena, general weakness, increased fatigue, dizziness, drowsiness, arterial hypotension, bradycardia.

If any adverse reactions occur, the patient should consult a doctor.

Potentiates the antianginal effects of nitrates, β-blockers, calcium antagonists, antihypoxants, neuroprotectors, cardiac glycosides. Reduces the manifestations of digitalis intoxication. The drug should not be used together with class III antiarrhythmics, cisapride.

In the original packaging at a temperature not exceeding 25 °C.

Keep out of reach of children.

Shelf life 3 years.

Do not use after the expiry date stated on the packaging.